High incidence of somatic BAP1 alterations in sporadic malignant mesotheliomaSafety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinEGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinibIs the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung CancersBevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic ReviewUpdate on HER1-3 in advanced non-small-cell lung cancerSurvival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysisThe relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysisPatient-centered outcomes among lung cancer screening recipients with computed tomography: a systematic reviewImmune therapies for lung cancerTumor vasculature as a therapeutic target in non-small cell lung cancerHistologic classification of thymoma: a practical guide for routine casesConsensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancerHsp90 inhibitorsIncorporating immune-checkpoint inhibitors into systemic therapy of NSCLCPrimary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysisA tabulated summary of targeted and biologic therapies for non-small-cell lung cancerFollow-up of patients after stereotactic radiation for lung cancer: a primer for the nonradiation oncologistSurgery in mesothelioma--where do we go after MARS?Angiogenesis inhibitorsTargeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung CancerMesotheliomaWhat is the most effective follow-up model for lung cancer patients? A systematic review.Maintenance therapy in advanced non-small cell lung cancer.Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.A patient with lung adenocarcinoma and RET fusion treated with vandetanib.Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
P1433
Q24170431-7323C0B2-A596-4304-B7E8-EC4ED32FCF8FQ24605776-60CEA5E0-F998-4FC4-8232-6DE961106FDEQ24606177-4B8A6430-1F37-46AE-AC4D-9FFBB72B369BQ26748741-3DD73A5E-A5F2-4F68-A558-A0477B030876Q26771375-ED3F9E35-4C8B-4871-8C73-578D55B5F9ABQ26801016-13394AC7-DAE9-4945-879D-9EDB5D76CD25Q26824058-B5571367-DE5B-4E8F-A646-FA445625472DQ26829819-4B48CC56-DBE4-4053-8622-1361421C3672Q26850684-4232596A-6921-4128-808E-6AB962F9A1BBQ26853166-B43DF51E-7A71-42DA-BD30-1515988CAE66Q26853248-F563AAA7-54F5-482C-A614-BDE5B70CE68BQ26863250-1E4CBF82-1B24-40EA-8337-CE56683F283DQ26863626-AA71B4BE-578E-419E-90F3-BABC979CD31CQ26865266-27E068CB-C04C-4208-9F00-A05DC0B7ECD6Q26993837-027602F3-278E-4A65-92C3-1E0C73CFE2CCQ26996582-7AD5BE6B-86F7-486E-9909-BE8AA94BAC16Q27003737-3A279032-1E96-44DB-8C5F-E21E3DF7166AQ27011523-A335FC77-2E1F-47CF-9663-7F169E7E6C81Q27022423-0891B9E9-C476-47D0-8AC8-1FDFBAA53E66Q27024612-7CE857F5-9289-426F-BAC2-945BF9DA4613Q27025839-7B9AB5A8-AAD0-45B4-85D5-280DE8E673B2Q27027743-92C954BD-F5B8-4F94-912E-B70CCD726E53Q27027744-C28AD2A1-AFE9-446E-8FF9-04D693D59AA3Q27692019-5A0CA042-7B0A-4F19-B3F5-794BC0160E88Q27693286-D388355E-254C-4676-9EA9-53AF9DD7C27EQ27851651-7B18F1D9-300E-487A-A8FC-6B3F002F5EEEQ27851652-91F07BEA-CE55-48F3-A187-12ED440E5367Q27851664-46C745FC-E335-454C-AA6D-3155CD870DB6Q27851673-989873A7-5FB7-4E21-A8C7-B47012E2B0BDQ27851784-881F26D2-7832-4C3B-8D9C-C8D95D7F5990Q27852049-CA6DCEDD-464B-4983-8321-5741CD5604DAQ27852128-05AE334E-5436-4D70-975F-D6613B38EA87Q27852203-8ABEFE9E-99E3-4432-A79B-8372F082C490Q27852984-72F03476-6DD6-40D2-B19C-7BE68D096ED8Q27852995-1489E5FE-09BB-4AC1-963B-A2CDE883703BQ27853089-7BE53365-00AB-4132-BBF8-8CDF2B709C92Q27853109-32AAAC3B-3907-4F4A-AEF9-568F67EFFFD3Q27853143-E47442A6-A41E-4401-97B1-49372E14EAF9Q27853309-6F387BBB-2A90-4880-8137-39573DFA80E9Q27853349-A2CF94B8-4F09-4BAA-82CF-027F6582C6A5
P1433
description
Medical journal
@en-gb
Medizinische Fachzeitschrift
@de
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
scientific journal
@en
vědecký časopis
@cs
wetenschappelijk tijdschrift van Elsevier
@nl
науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Journal of Thoracic Oncology
@ast
Journal of Thoracic Oncology
@da
Journal of Thoracic Oncology
@de
Journal of Thoracic Oncology
@en
Journal of Thoracic Oncology
@en-ca
Journal of Thoracic Oncology
@en-gb
Journal of Thoracic Oncology
@es
Journal of Thoracic Oncology
@fi
Journal of Thoracic Oncology
@fr
Journal of Thoracic Oncology
@it
type
label
Journal of Thoracic Oncology
@ast
Journal of Thoracic Oncology
@da
Journal of Thoracic Oncology
@de
Journal of Thoracic Oncology
@en
Journal of Thoracic Oncology
@en-ca
Journal of Thoracic Oncology
@en-gb
Journal of Thoracic Oncology
@es
Journal of Thoracic Oncology
@fi
Journal of Thoracic Oncology
@fr
Journal of Thoracic Oncology
@it
altLabel
J. Thorac. Oncol.
@de
J. Thorac. Oncol.
@en
J. Thorac. Oncol.
@en-gb
J. Thorac. Oncol.
@fr
prefLabel
Journal of Thoracic Oncology
@ast
Journal of Thoracic Oncology
@da
Journal of Thoracic Oncology
@de
Journal of Thoracic Oncology
@en
Journal of Thoracic Oncology
@en-ca
Journal of Thoracic Oncology
@en-gb
Journal of Thoracic Oncology
@es
Journal of Thoracic Oncology
@fi
Journal of Thoracic Oncology
@fr
Journal of Thoracic Oncology
@it
P243
P3181
P4616
P1055
P1058
P1156
6400153137
P123
P1250
P1277
P1476
Journal of Thoracic Oncology
@en
P236
P243
P407
P571
2006-01-01T00:00:00Z
P5963
journal-of-thoracic-oncology